Activity and concentration of cathepsin B as prognostic criteria for the development of mouse LS lymphosarcoma and Lewis lung adenocarcinoma

Bulletin of Experimental Biology and Medicine

Volumn 133, Issue 4, 2002, Pages 392-395

  Korolenko, T A ^a,b,c   Zhyanaeva, S Ya ^a,b,c   Poteryaeva, O N ^a,b,c   Falameeva, O V ^a,b,c   Levina, O A ^a,b,c   Kaledin, V I ^a,b,c   Shandula, I ^a,b,c  

^a ENERGY SYSTEMS INSTITUTE   (Russian Federation)

^b INSTITUTE OF CYTOLOGY AND GENETICS   (Russian Federation)

^c INSTITUTE OF CHEMISTRY   (Slovakia)

Author keywords

Activity and concentration; Cathepsin B; Enzyme immunoassay; Lewis lung adenocarcinoma; LS lymphosarcoma

Indexed keywords

ANTINEOPLASTIC AGENT; BETA 1,3 DEXTRO CARBOXYMETHYLGLUCAN; CA 074; CATHEPSIN B; CYCLOPHOSPHAMIDE; CYSTEINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INHIBITION; LEWIS CARCINOMA; LIVER; LYMPHOSARCOMA; MALE; METASTASIS; MOUSE; NONHUMAN; PROGNOSIS; SPLEEN; TUMOR;

ANIMALS; CARCINOMA, LEWIS LUNG; CATHEPSIN B; LIVER; LYMPHOMA, DIFFUSE; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED CBA; PROGNOSIS; SPLEEN; TUMOR MARKERS, BIOLOGICAL;

ANIMALIA;

EID: 0036554837     PISSN: 00074888     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1016214508692     Document Type: Article

References (16)

1. O. N. Poteryaeva, O. V. Falameeva, S. Ya. Djanayeva, et al., Byull. Eksp. Biol. Med., 132, No. 7, 77-79 (2001).
2. O. V. Falameeva, O. N. Poteryaeva, S. Ya. Djanayeva, et al., Ibid., 132, No. 8, 205-208 (2001).
3. A. J. Barrett and H. Kirschke, Methods Enzymol., 80, 535-561 (1981).
4. A. Donchin, J. I. Suzuki, H. Seki, et al., Cancer, 89, 482-487 (2000).
5. L. Foghsgaard, D. Wissing, D. Mauch, et al., J. Cell Biol., 153, 999-1010 (2001).
6. B. A. Frosch, I. Berquin, M. R. Emmert-Buck, et al., APMIS, 107, 28-37 (1999).
7. J. T. Koblinski and B. F. Sloane, Medical Aspects of Proteases and Protease Inhibitors, Eds. N. Katunuma et al., Amsterdam (1997), pp. 185-194.
8. T. A. Korolenko, O. N. Poteryaeva, S. J. Djanayeva, et al., Drugs Exp. Clin. Res., 26, No. 5-6, 285-292 (2000).
9. J. Kos, B. Werle, T. Lah, and N. Brunner, Int. J. Biol. Markers, 15, No. 1, 87-89 (2000).
10. T. T. Lah, M. Cercek, A. Blejec, et al., Clin. Can. Res., 6, 578-584 (2000).
11. K. Moin, L. Cao, N. A. Day, et al., Biol. Chem., 379, 1093-1099 (1998).
12. C. L. Monito, D. Berkowitz, K. M. Lee, et al., Am. J. Physiol. Endocrinol. Metab., 281, 289-297 (2000).
13. O. N. Poteryaeva, O. V. Falameyeva T. A. Korolenko, et al., Drugs Exp. Clin. Res., 26, No. 5-6, 137-142 (2000).
14. A. A. Sinha, B. J. Quast, M. J. Wilson, et al., Prostate, 48, 274-284 (2001).
15. T. Strojnik, T. Zajc, A. Bervar, et al., Pflugers Arch., 439, R122-R123 (2000).
16. A. M. Szpaderska and A. Frankfater, Cancer Res., 61, 3493-3500 (2001).